Risks
4 risks
Risk Intelligence
Sustained pricing pressure in generics
View Risks →
Alembic Pharmaceuticals Limited — Q4 FY26
Alembic Pharmaceuticals reported Q4 FY26 revenue of ₹1,848 crore, up 4% YoY, with core EBITDA margin before R&D at 25% (vs 24% YoY).
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Alembic Pharmaceuticals reported Q4 FY26 revenue of ₹1,848 crore, up 4% YoY, with core EBITDA margin before R&D at 25% (vs 24% YoY). PAT of ₹203 crore included exceptional items and tax adjustments. India business grew 4% YoY, US showed volume-led growth, and API grew modestly. Management guided for low double-digit consolidated revenue growth in FY27, with R&D spend of ₹750-800 crore and capex of ₹300-350 crore. The US branded business (Pivya launch) is expected to be a near-term margin drag of 100-150 bps, offset by core operating leverage. Risks include sustained pricing pressure in generics, delayed ramp-up of new facilities, and execution risk in the branded specialty pivot.
एलेम्बिक फार्मास्युटिकल्स ने चौथी तिमाही (जनवरी-मार्च 2026) में ₹1,848 करोड़ की कमाई की, जो पिछले साल से 4% ज्यादा है। कंपनी का मुख्य मुनाफा (R&D खर्च से पहले) 25% रहा, जो पिछले साल 24% था। कुल मुनाफा ₹203 करोड़ रहा, जिसमें कुछ एकमुश्त खर्च और टैक्स एडजस्टमेंट शामिल हैं। भारत में कारोबार 4% बढ़ा, अमेरिका में बिक्री मात्रा बढ़ने से हुई, और API (दवा बनाने का कच्चा माल) में मामूली बढ़ोतरी हुई। कंपनी ने अगले साल (FY27) 10-12% कमाई बढ़ने का अनुमान लगाया है। R&D पर ₹750-800 करोड़ और नई मशीनरी पर ₹300-350 करोड़ खर्च होंगे। अमेरिका में नए ब्रांडेड बिज़नेस (पिव्या लॉन्च) से शुरुआत में मुनाफे पर 1-1.5% का दबाव पड़ेगा, लेकिन बाद में सुधार होगा। जोखिमों में जेनेरिक दवाओं पर कीमत दबाव, नए प्लांट की देरी और ब्रांडेड बिज़नेस में बदलाव की चुनौतियां शामिल हैं।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Business Growth (Q4)
4%
+4% YoY
India business grew 4% YoY in Q4, supported by price-led growth and new launches.
Ex-US Market Growth (FY26)
20%
+20% YoY
Ex-US markets grew 20% for the full year, though Q4 was muted due to a high base.
US Business Growth Guidance (FY27)
10-15%
Guidance
Management expects US business to grow 10-15% in FY27 in INR terms.
R&D Spend Guidance (FY27)
₹750-800 crore
Increase vs FY26
R&D spend guided at ₹750-800 crore for FY27, up from FY26 levels, driven by peptide and complex filings.
What Changed vs Last Quarter
NEW
Low double-digit consolidated revenue growth in FY27
Management targets low double-digit topline growth for FY27 at consolidated level.
NEW
R&D spend of ₹750-800 crore in FY27
R&D investments expected to be around ₹750-800 crore, focusing on complex and peptide developments.
NEW
Capex of ₹300-350 crore in FY27
Capital expenditure guided at ₹300-350 crore, primarily for capacity debottlenecking and replacement.
NEW
US branded business to scale meaningfully in next few quarters
With Pivya launch, branded franchise expected to reach meaningful revenue profile in next few quarters.
DROPPED
US business full-year growth of 10-12%
Management expects US business to grow 10-12% for the full year FY26, driven by volume growth and new launches.
DROPPED
India branded business to align with market growth by Q1 FY27
Management expects India branded business growth to converge with the market growth rate by Q1 of the next financial year.
DROPPED
R&D spend of ₹600-650 crore for FY26
Full-year R&D spend guidance of ₹600-650 crore, representing 8-9% of revenue.
DROPPED
Pivya launch in Q4 FY26
First branded product Pivya to be launched in the US in Q4 FY26, with prescription share scaling over 12-18 months.
NEW RISK
US branded business margin drag
The launch of Pivya and the US branded specialty business will drag margins by 100-150 bps in the near term, with uncertain timing of breakeven.
NEW RISK
R&D productivity and elevated spend
R&D spend increased to 11% of revenue in Q4, and guidance for FY27 is elevated at ₹750-800 crore; returns on this investment are uncertain.
NEW RISK
New facility ramp-up delays
F2 and F3 facilities are still underutilized (40-60% on some lines), and revenue contribution from contract manufacturing may take time to materialize.
RISK GONE
India branded business underperformance
India branded business grew only 6% YoY, below market growth, and management has not provided a clear timeline for improvement beyond Q1 FY27.
RISK GONE
Pivya launch margin drag
The branded product Pivya launch will impact near-term profitability, with management unable to quantify the margin impact.
RISK GONE
Dependence on injectable and complex generics for future growth
Management expects injectables and complex generics to drive US growth over the next 2-3 years, but approvals and ramp-up remain uncertain.
Fast read
Guidance and risk preview
Management targets low double-digit topline growth for FY27 at consolidated level.
Pricing pressure and competitive intensity continue to impact the US and API businesses, potentially limiting margin expansion.
View Risks →